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REVIEW
Abstract: Endothelial dysfunction is a well established response to cardiovascular risk factors
and precedes the development of atherosclerosis. Endothelial dysfunction is involved in lesion
formation by the promotion of both the early and late mechanisms of atherosclerosis including
up-regulation of adhesion molecules, increased chemokine secretion and leukocyte adherence,
increased cell permeability, enhanced low-density lipoprotein oxidation, platelet activation,
cytokine elaboration, and vascular smooth muscle cell proliferation and migration. Endothelial
dysfunction is a term that covers diminished production/availability of nitric oxide and/or an
imbalance in the relative contribution of endothelium-derived relaxing and contracting factors.
Also, when cardiovascular risk factors are treated the endothelial dysfunction is reversed and
it is an independent predictor of cardiac events. We review the literature concerning endothelial
dysfunction in regard to its pathogenesis, treatment, and outcome.
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Introduction
During the last 2 decades, it has been shown that the vascular endothelium is an
active paracrine, endocrine, and autocrine organ that is indispensable for the regulation
of vascular tone
 and the maintenance of vascular homeostasis. The basic mechanisms
involved in atherogenesis
 indicate that deleterious alterations of endothelial
physiology, otherwise known as endothelial dysfunction, represent a key early step
in the development of atherosclerosis and are also
 involved in plaque progression
and the occurrence of atherosclerotic
 complications (Anderson, Gerhard, et al 1995;
Kinlay and Ganz 1997). Endothelial dysfunction is characterized by reduction of the
bioavailability of vasodilators, particularly nitric oxide
 (NO), and/or an increase in
endothelium-derived contracting factors (Lerman and Burnett 1992). The resulting
imbalance leads to an impairment of endothelium-dependent
 vasodilation, which is
the functional characteristic of endothelial dysfunction.
 In addition to impaired
endothelium-dependent vasodilation, endothelial dysfunction
 also comprises a specific
state of endothelial activation, which is characterized by a proinflammatory,
proliferative,
 and procoagulatory states that favor all stages of atherogenesis (Anderson
1999). Considering the relationship between endothelial dysfunction and
atherosclerosis, it is likely that the status of an individual endothelial
 function may
reflect the propensity to develop
 atherosclerotic disease, and thus may serve as a
marker of an unfavorable cardiovascular
 prognosis. Herein, we review the literature
about endothelial dysfunction in regard to its pathogenesis, treatment, and outcome.
Pathophysiology of endothelial dysfunction
The endothelium maintains normal vascular tone and blood fluidity, with no or little
expression of proinflammatory factors under normal homeostatic conditions.
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However, both traditional and novel cardiovascular risk
factors including smoking, aging, hypercholesterolemia,
hypertension, hyperglycemia, and a family history of
premature atherosclerotic disease are all associated with
alteration in endothelial function (Sorensen et al 1994;
Gokce and Vits 2002; Libby et al 2002). This results in a
chronic inflammatory process accompanied by a loss of
antithrombotic factors and an increase in vasoconstrictor
and prothrombotic products, in addition to abnormal
vasoreactivity, therefore elevating risk of cardiovascular
events (Bonetti et al 2003) (Figure 1). More recently,
endothelial dysfunction has also been associated with
obesity, elevated C-reactive protein, and chronic systemic
infection (Celermajer et al 1992; Steinberg et al 1996;
Thogersen et al 1998; Cushman et al 1999; Fichtlscherer et
al 2000; Al Suwaidi et al 2001; Prasad et al 2002).
Oxidative stress and endothelial cell
dysfunction
Reactive oxygen species (ROS) are generated at sites of
inflammation and injury, and at low concentrations can
function as signaling molecules participating in the
regulation of fundamental cell activities such as cell growth
and cell adaptation responses; whereas at higher
concentrations, ROS can cause cellular injury and death.
The vascular endothelium, which regulates the passage of
macromolecules and circulating cells from blood to tissues,
is a major target of oxidative stress, playing a critical role in
the pathophysiology of several vascular diseases and
disorders. Specifically, oxidative stress increases vascular
endothelial permeability and promotes leukocyte adhesion,
which is coupled with alterations in endothelial signal
transduction and redox-regulated transcription factors (Lum
and Roebuck 2001).
How is endothelial function
assessed?
Endothelium-dependent vasodilation can be assessed in the
coronary and peripheral circulations. The most relevant
methodological issues in the research on endothelial function
and dysfunction have recently been published (Deanfield
et al 2005). We provide a summary of the available
modalities of testing.
Coronary circulation
Noninvasive tests
 for the assessment of coronary endothelial
function that have been described include Doppler
echocardiography, positron emission tomography, and
phase-contrast magnetic resonance imaging. However, the
gold standard test for the evaluation of coronary endothelial
function requires invasive quantitative coronary angio-
graphy to examine the changes in diameter in response to
intracoronary infusions of endothelium-dependent
vasodilators such as acetylcholine. Endothelial function
 of
the coronary microvasculature can be assessed with
intracoronary Doppler techniques to measure coronary
blood flow in response
 to pharmacological or physiological
stimuli (Anderson 1999; Al Suwaidi et al 2001; Farouque
and Meredith 2001). Diagnostic coronary angiography is
first performed with a standard femoral percutaneous
approach, with no nitroglycerin given beforehand.
Vasomotor responses to acetylcholine and adenosine are
then assessed (Al Suwaidi et al 2001). After the control
coronary angiogram has been obtained, a 0.014-inch
Doppler guide wire is introduced through an 8-F guiding
catheter into the left anterior descending coronary artery.
Once baseline flow velocity data are obtained at the position,
ie, once a stable Doppler signal is achieved, a bolus of
intracoronary adenosine (24–36 µg, from a solution of 6 mg
adenosine in 1  L of saline) is administered. Then intra-
coronary infusion of selective concentrations of
acetylcholine (10–6, 10
–5, and 10
–4 mol/L) is administered
for a total of 3 minutes through a 2.2-F Ultrafuse coronary
infusion catheter. Symptoms, hemodynamic data, and
electrocardiographic and Doppler velocities are recorded
at the end of each infusion or bolus injection, followed by
selective coronary angiogram. Coronary blood flow is
calculated using the formula D² × APV, where D represents
the coronary diameter and APV equals the average peak
velocity from Doppler tracing.
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Figure 1 The various factors that affect the endothelium and the consequences
of endothelial dysfunction.Vascular Health and Risk Management 2005:1(3) 185
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Peripheral circulation
Brachial artery ultrasound is a widely used noninvasive
measure
 of endothelial function. Upper-arm occlusion for
5 minutes results
 in reactive hyperemia after the release of
the cuff; the increase
 in shear stress results in endothelium-
dependent flow-mediated vasodilation. Importantly,
endothelial dysfunction assessed
 by this technique correlates
with measures of coronary endothelial
 dysfunction
(Anderson, Uehata, et al 1995). Peripheral vascular
endothelial function can be
 assessed by strain-gauge venous
impedance plethysmography. This technique examines the
change in forearm blood flow in response to direct intra-
arterial (brachial artery) administration of agonists.
Noninvasive measures of arterial compliance and waveform
morphology provide a marker of vascular health
 (Deanfield
et al 2005).
Role of endothelial dysfunction in
acute coronary syndromes
Endothelial dysfunction may play a fundamental role in the
pathogenesis of acute coronary syndromes (Libby 2001).
Plaque destabilization, the process
 that predisposes to
rupture of the plaque, results from a complex interplay of
inflammatory effects that involve cellular plaque
components and various proinflammatory mediators (Libby
et al 2002). Endothelial
 dysfunction is associated with
increased oxidative stress (Napoli et al 2001), an
 important
promoter of inflammatory processes. NO may reduce
endothelial expression of several inflammatory mediators
and
 adhesion molecules that increase plaque vulnerability
(Kubes et al 1991; De Catarina et al 1995; Peng et al 1995;
Barnes and Karin 1997). Precipitation of acute coronary
syndrome may also involve physical factors related
 to
endothelial dysfunction. Increased vasoreactivity results in
local vasoconstriction in response to metabolic and
sympathetic stimuli in the area of culprit lesions in
 patients
with unstable angina (Bogaty et al 1994). All of these
processes may contribute to plaque rupture and hence the
development of acute coronary syndrome.
Endothelial dysfunction and
cardiovascular risk factors
Diabetes and endothelial dysfunction
Molecular and cellular basis of endothelial
dysfunction in diabetes
Hyperglycemia
 may lead to intracellular changes in the
redox state resulting in depletion of the cellular NADPH
pool. Overexpression of growth factors has also been
implicated in diabetes with proliferation of both endothelial
cells and vascular smooth muscle, possibly promoting
neovascularization. Chronic hyperglycemia leads to non-
enzymatic glycation of proteins and macromolecules
(Calles-Escandon and Cipolla 2001).
The diabetic state is typified by an increased tendency
for oxidative stress and high levels of oxidized lipoproteins,
especially the so-called small, dense low-density lipoprotein.
The high levels of fatty acids and hyperglycemia have also
both been shown to induce an increased level of oxidation
of
 phospholipids as well as proteins. In humans it is
associated with a prothrombotic tendency
 as well as
increased platelet aggregation, with tumor necrosis factor
implicated as a link
 between insulin resistance, diabetes, and
endothelial dysfunction; a hypothesis
 has been advanced that
insulin and/or insulin precursors may be atherogenic (Calles-
Escandon and Cipolla 2001).
We have reviewed 22 experimental and clinical studies
from 1991 to 2004 that evaluated endothelial dysfunction
in diabetic patients; most of these were prospective studies.
Diminished capacity of NO synthase to generate NO has
been demonstrated experimentally when endothelial cells
were exposed either in vitro or in vivo to a diabetic
environment (Arbogast et al 1982; Aanderud et al 1985;
Koh et al 1985; Lorenzi et al 1986; Hattori et al 1991; Nordt
et al 1993; Avogaro et al 1999; Cipolla 1999; Salvolini et al
1999). Most of these studies in humans indicate that
endothelial dysfunction is closely associated with
microangiopathy
 and atherosclerosis in diabetic patients.
Endothelial dysfunction in insulin-dependent
diabetes mellitus
The association between diabetes and endothelial
dysfunction is particularly true in patients with type 1
diabetes who have either early (microalbuminuria)
 or late
(macroalbuminuria) nephropathy. A
 variety of markers
indicate endothelial dysfunction: poor
 endothelial cell-
dependent vasodilation and increased blood levels of von
Willebrand factor (vWF), thrombomodulin, selectin,
plasminogen activator inhibitor, type IV collagen, and tissue
plasminogen activator (t-PA) have been demonstrated in this
patient population (Yaqoob et al 1993; Dosquet et al 1994;
Myrup et al 1994; Makimattila et al 1996; Huszka et al 1997;
Cosentino and Luscher 1998; Elhadd et al 1998; Malamitsi-
Puchner et al 1998; Huvers et al 1999). While the
dysfunction of endothelial cells is considered to be an early
marker of vascular disease in type 2 diabetes, it does notVascular Health and Risk Management 2005:1(3) 186
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seem to fully manifest itself until later in the course of type
1 diabetes (Clarkson et al 1996). Furthermore, it has been
shown that the levels of vascular cell adhesion molecule-1
were
 more markedly elevated in type 1 diabetes patients with
diabetic retinopathy than in those with micro- or
macroalbuminuria, whereas
 no difference in intracellular
adhesion molecule-1 and endothelial leukocyte adhesion
molecule-1 levels was apparent regarding
 the clinical status
of diabetic microangiopathy (Fasching et al 1996). In
diabetic subjects, endothelium-dependent
 vasodilation
correlated inversely with serum insulin concentration but
not with glucose concentration, glycosylated hemoglobin,
or duration of diabetes (Johnstone et al 1993).
In another study, a significantly raised mean
concentration of a free N-terminal fibronectin 30-kDa
domain (a marker of endothelial dysfunction) was found in
plasma of diabetic patients with proliferative
 retinopathy as
compared with healthy individuals, and a positive correlation
was observed between free N-terminal fibronectin and vWF
and the degree of albuminuria, suggesting an association
between endothelial cell dysfunction and proliferative
retinopathy (Skrha et al 1990).
The general consensus is that the occurrence of
endothelial cell dysfunction
 in type 1 diabetes signifies a
very high risk of micro- and macroangiopathy,
 and although
the diabetic state predisposes to endothelial cell dysfunction
in this disease, it is not sufficient to cause it. It is more likely
that other agents (genes, environment) have a role
 in
determining which patients will develop aggressive
angiopathy
 and hence endothelial cell dysfunction.
Irrespective of whether endothelial cell dysfunction is a
cause or a consequence of vascular injury in type 1 diabetes,
it is hoped that therapeutic efforts aimed at restoring
endothelial cell function to normal will affect the natural
history of vasculopathy
 in type 1 diabetes (Calles-Escandon
and Cipolla 2001).
Endothelial dysfunction in non-insulin-dependent
diabetes mellitus
The role of endothelial dysfunction in type 2 diabetes is
more complicated than that for type 1. The effects of aging,
hyperlipidemia, hypertension,
 and other factors add to the
complexity of the problem. In contrast to the situation with
type 1 diabetes, endothelial dysfunction can occur in type 2
diabetes even when patients have
 normal urinary albumin
excretion, a marker of endothelial dysfunction often elevated
years before any evidence of microangiopathy
 becomes
evident (Janka 1985; Hsueh and Anderson 1992;
Bloomgarden 1998; De Mattia et al 1998; Neri et al 1998;
Watts and Playford 1998; Gazis et al 1999).
There is growing evidence suggesting the coexistence
of insulin resistance and endothelial dysfunction. Insulin-
induced vasodilation,
 which is partially mediated by NO
release, is impaired in obese individuals who do not have
type 2 diabetes but who display
 insulin resistance (Steinberg
et al 1994; Ferri et al 1997). Moreover, the obese state, a
model
 of human insulin resistance, is associated with high
levels of endothelin in plasma. Plasminogen activator
inhibitor concentrations in blood also are high in patients
with otherwise uncomplicated obesity (Calles-Escandon et
al 1996).
The insulin resistance syndrome encompasses more than
a subnormal response
 to insulin-mediated glucose disposal;
patients with this syndrome also frequently display elevated
blood pressure, hyperlipidemia,
 and dysfibinolysis even
without any clinically demonstrable
 alteration in plasma
glucose concentrations (Steinberg et al 1994).
The vasodilatory responses to acetylcholine
 have been
shown to be reduced in healthy normoglycemic individuals
with a history of type 2 diabetes in one or both parents
(relatives), individuals with impaired glucose tolerance, and
patients with type 2 diabetes without vascular complications
compared with healthy normoglycemic individuals
 with no
history of type 2 diabetes in a first-degree relative (as
control). The
 plasma levels of endothelin-1 were
significantly higher in these three
 groups. These results
suggest that abnormalities in vascular reactivity and
biochemical markers of endothelial cell activation are
present early in individuals at risk of
 developing type 2
diabetes (Caballero et al 1999).
Low and high physiological hyperinsulinemia have been
shown to
 abolish endothelium-dependent vasodilation,
whereas endothelium-independent vasodilation was
unaffected. Vitamin C fully restored insulin-impaired
endothelial function without affecting endothelium-
independent
 vasodilation (Arcaro et al 2002). Other
investigators concluded that insulin
 therapy partly restores
insulin-stimulated endothelial function in patients with type
2 diabetes and ischemic heart disease (Rask-Madsen et al
2001). In other studies in which the long-term effects of
insulin glargine on vascular function in patients with type 2
diabetes were investigated, the results seem to support the
idea that long-term insulin therapy has
 beneficial rather than
harmful effects on vascular function (Paolisso and GiuglianoVascular Health and Risk Management 2005:1(3) 187
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1996; Vehkavaara and Yki-Jarvinen 2001). A recently
performed double-blind, crossover trial of 12 patients with
recently diagnosed type 2 diabetes concluded that insulin
resistance is a major contributor to endothelial dysfunction
in type 2 diabetes, with both endothelial dysfunction and
insulin resistance amenable to treatment by rosiglitazone
(Pistrosch et al 2004). In a more recent study in which the
relationship between the angiotensin-converting enzyme
(ACE) gene and endothelial dysfunction was investigated,
it was concluded that ACE DD genotype is related to
endothelium-dependent arterial dilation in the early stage
of type 2 diabetes mellitus and in healthy individuals (Xiang
et al 2004).
Several
 therapeutic interventions have been tested in
clinical trials with the aim of improving endothelial function
in patients with diabetes. Insulin sensitizers may have a
beneficial effect in the short and the long term,
 but the virtual
absence of trials with cardiovascular end points precludes
any definitive conclusion. Several trials offer optimism that
treatment with ACE inhibitors may have a positive effect on
the progression
 of atherosclerosis (O’Driscoll, Green,
Rankin, et al 1997; Mullen et al 1998; O’Driscoll et al 1999;
Prasad et al 2000; Hornig et al 2001). Although
hypolipidemic
 agents are widely used, their effect on
endothelial function in diabetes is not clear (Evans et al
2000). The
 role of antioxidant therapy remains controversial
(Table 1).
Endothelial dysfunction in hypertension
Endothelial dysfunction has been documented in both the
forearm and coronary beds of patients with essential
hypertension. We evaluated 111 patients with normal or mild
coronary artery disease by intracoronary Doppler and
intravascular ultrasound examination of the left anterior
descending coronary artery. Patients were divided into three
groups: hypertensive with left ventricular hypertrophy
(LVH) (n = 13), hypertensive without LVH (n = 30), and
normotensive (n = 68). We found that vessel area and
coronary blood flow in patients with LVH were significantly
greater than in patients in the other two groups (p < 0.01,
p < 0.05); furthermore, the response to both acetylcholine
and adenosine was significantly impaired in patients with
LVH (Hamasaki et al 2000), indicating that endothelium-
dependent and -independent vasodilation were impaired in
patients with hypertension and LVH.
We have reviewed several other prospective studies that
evaluated different aspects of endothelial dysfunction in
patients with systemic hypertension; salt-sensitive
hypertension is also associated with endothelial dysfunction
characterized by defective endothelium-dependent
vasodilation. Impairment of the L-arginine-NO pathway may
be responsible for this abnormal endothelial response
(Bragulat et al 2001). Another study found that potassium
increases endothelium-dependent vasodilation in essential
hypertensive patients (Taddei et al 1994); the same
investigator demonstrated impairment of endothelium-
dependent vasodilation in renovascular and primary
aldosteronism hypertensive patients and indicated that a
cyclooxygenase-dependent vasoconstrictor mechanism
participated in the blunting of endothelium-dependent
vasodilation in essential hypertensive patients (Taddei et al
1993). Other investigators studying the vascular effect of
the arginine analog NG-monomethyl-L-arginine have found
that patients with essential hypertension have a defect in
the endothelium-derived NO system that may at least partly
account for both the increased vascular resistance under
basal conditions and the impaired response to endothelium-
dependent vasodilators (Panza, Casino, et al 1993). Evidence
from the same group has led to the conclusion that the
endothelial abnormality of patients with essential
hypertension is not restricted to the muscarinic receptors
(Panza et al 1994) and clinically effective antihypertensive
therapy does not restore the impaired endothelium-
dependent vasorelaxation in patients with essential
hypertension. This indicates that such endothelial
dysfunction is either primary, or becomes irreversible once
the hypertensive process has become established (Panza,
Quyyumi, et al 1993). Another study has shown that the
endothelium-dependent vasodilatory response to
acetylcholine in the forearm resistance arteries is impaired
in patients with essential hypertension (Yoshida et al 1991).
In contrast, it has also been argued that selective impairment
of the responsiveness of the forearm vasculature to
muscarinic agonists is not universal in patients with essential
hypertension (Cockcroft et al 1994).
Endothelial dysfunction and aging
Vascular cells have a finite lifespan when cultured in vitro
and eventually enter an irreversible growth arrest called
“cellular senescence”. Recently, senescent vascular cells
have been demonstrated in human atherosclerotic lesions
but not in non-atherosclerotic lesions. Moreover, these cells
express increased levels of proinflammatory molecules and
a decreased level of endothelial NO synthase, suggestingVascular Health and Risk Management 2005:1(3) 188
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Table 1 Modes of therapy of endothelial dysfunction
Result on
endothelial
References Treatment Patient condition function
Creager et al 1992; Quyyumi et al 1997; Boger et al 1998  L-arginine Hypercholesterolemia, CAD, heart failure  + EDVD
intravenous, oral – EIDVD
intracoronary
Creager et al 1992; Boger et al 1998  D-arginine Hypercholesterolemia, CAD, heart failure No effect
Thorne et al 1998; Wang et al 1999 Oral arginine Hypercholesterolemia, CAD, heart failure Debated
Andrews et al 2001 N-acetylcysteine CAD + EDVD
O’Driscoll, Green, Rankin, et al 1997; Hernandez-Perera Statins DM type 1, DM type 2, CAD, regardless of + EDVD
et al 1998; Dupuis et al 1999; Lefer et al 1999; Yokoyama lipid level
et al 1999; Vita et al 2000; Masumoto et al 2001; Stein
et al 2001
Evans et al 2000 Fibrates DM  + EDVD
Ryan et al 2000; Fuentes et al 2001 Mediterranean diet CAD + EDVD
DeSouza et al 2000 Regular aerobic Young, old sedentary  + EDVD
exercise
Ziccardi et al 2002 Weight loss Premenopausal obese women + EDVD
Ting et al 1997; Verhaar et al 1999; Chambers et al 2000;  Antioxidant, vitamin C, Coronary microcirculation + EDVD
Kaufmann et al 2000; Stuhlinger et al 2001 folate, tetrahydrofolate
Skyrme-Jones, O’Brien, Berry, et al 2000; Skyrme-Jones, Vitamin E DM + EDVD
O’Brien, Luo, et al 2000 
Sesso 1999; Chou et al 2001; Duffy et al 2001 Flavonoids CAD + EDVD
Guthikonda et al 2003 Allopurinol Smokers + EDVD
Husain et al 1998 Aspirin CAD + EDVD
Gilligan, Quyyumi, et al 1994; Venkov et al 1996;  Estrogen CAD, hypercholesterolemia + EDVD
Thompson et al 2000; Webb et al 2000
Wakatsuki et al 2001 Progesterone CAD Offset estrogen
effect
Clarke et al 2001; Wassmann et al 2002 Tamoxifen, raloxifene CAD + EDVD
Lissin and Cooke 2000; Walker et al 2001 Phytoestrogen Normal +  EDVD
Webb et al 1999 Testosterone CAD  + EDVD
Bijlstra et al 1995; Mancini et al 1996; O’Driscoll, Green, ACEI (most studies) DM, CAD + EDVD
Rankin, et al 1997; Mullen et al 1998; O’Driscoll
et al 1999; McFarlane et al 1999; Anderson et al 2000;
Prasad et al 2000; Hornig et al 2001
Cheetham et al 2000; Hornig et al 2001 ARB DM, CAD Debated results
Berger et al 2001; Cardillo et al 2002 Endothiline receptor Hypertension, heart failure  + EDVD
blockers
ENCORE I Study 2003 Nifedipine PCI + EDVD
Mather et al 2001 Metformin DM + EDVD
Tack et al 1998; Pistrosch et al 2004 Rosiglitazone DM + EDVD
Goodfellow et al 2000 Omega 3 fatty acid Hypercholesterolemia + EDVD
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CAD, coronary artery disease; DM, diabetes mellitus; EDVD,
endothelium-dependent vasodilation; EIDVD, endothelium-independent vasodilation; PCI, percutaneous coronary intervention.Vascular Health and Risk Management 2005:1(3) 189
Endothelial dysfunction
that cellular senescence in vivo contributes to the
pathogenesis of human atherosclerosis (Minamino et al
2004).
One widely discussed hypothesis of senescence is the
telomere hypothesis. Introduction of telomere malfunction
has been shown to lead to vascular dysfunction that promotes
atherogenesis, whereas telomere lengthening extends cell
lifespan and protects against vascular dysfunction associated
with senescence. More recent evidence suggests that
telomere-independent mechanisms are implicated in
vascular cell senescence. Activation of Ras, an important
signaling molecule involved in atherogenic stimuli, induces
vascular cell senescence and thereby promotes vascular
inflammation in vitro and in vivo. A large body of data is
consistent with cellular senescence contributing to age-
associated vascular disorders (Minamino et al 2004).
We reviewed published experimental and clinical studies
about aging and endothelial function, most of which were
small prospective studies. The hypothesis that oxidative
stress, particularly oxidation of tetrahydrobiopterin, may
contribute to attenuation of endothelium-dependent
relaxation was tested in aged mice using the vasomotor
function of isolated carotid arteries by video dimension
analyzer, while vascular levels of tetrahydrobiopterin and
its oxidation products were measured by high performance
liquid chromatography (Blackwell et al 2004). Evidence
presented seems to suggest that aging is associated with
endothelial dysfunction and reduced arterial elasticity. In
addition, reduced arterial elasticity parallels changes in
impaired endothelium-dependent vasodilation. It appears
that reduced arterial elasticity may be used as a noninvasive
measure for the determination of endothelial function (Tao
et al 2004). Another study concluded that there is a blunted
response to acetylcholine with advancing age in both
normotensive controls and essential hypertensive patients,
suggesting that aging is associated with reduced
endothelium-dependent vasodilation in humans (Taddei et
al 1995). In normotensive individuals, an earlier primary
dysfunction of the NO system and a later production of
oxidative stress cause age-related reduction in endothelium-
dependent vasodilation. These alterations are similar but
anticipated in hypertensive patients compared with
normotensive individuals (Taddei et al 2001).
High cholesterol and endothelial
dysfunction
Cholesterol is one of the most well established risk factors
for premature coronary artery disease (Multiple Risk Factor
Intervention Trial Group 1982). Cholesterol levels and
coronary artery disease risk show a strong and linear
relationship; hypercholesterolemia and high levels of total
cholesterol and low-density lipoprotein (LDL) cholesterol
result in impaired endothelial function in both peripheral
and coronary circulation (Creager et al 1990; Casino et al
1993). Studies concluded that cholesterol levels even in the
normal range may be inversely related to endothelium-
dependent vasodilation, and this finding has important
clinical implications. This suggests that lowering cholesterol
levels even when it is within the normal range may improve
the production and release of endothelium-dependent NO
and hence improve endothelial function (Masumoto et al
2001) (Table 1). This idea is supported by recent reports
that lowering cholesterol levels enhances endothelium-
dependent vasodilation not only in subjects with massively
elevated cholesterol levels but also in those with normal
cholesterol levels. It is worth noting that lowering of average
cholesterol levels in patients with documented coronary
artery disease leads to decreased rates of myocardial
infarction, and this protective effect may in part be due to
improvement in endothelial function (Gilligan, Guetta, et
al 1994; Casino et al 1995). In addition to lipid-lowering
therapy, administration of tetrahydrobiopterin, an essential
cofactor for NO production, could restore NO activity in
familial hypercholesterolemia (Verhaar et al 1999).
Obesity and endothelial dysfunction
The pathogenesis of vascular disease in obesity remains
unclear but probably relates to the effect of the metabolic
syndrome (insulin resistance, dyslipidemia, hyperoxidative
stress, and hypertension) on the biology of endothelium-
derived NO. The notion of increased oxidative stress in
central obesity is based on an expansion of the cytosolic
triglyceride storage pool in non-adipose tissue (Bakker et
al 2000). The accumulation of long-chain fatty acyl-
coenzyme A esters is hypothesized to inhibit mitochondrial
adenosine translocation, with subsequent overproduction of
oxygen free radicals such as superoxide. Strong evidence is
accumulating that antioxidants may improve insulin
resistance and endothelial dysfunction (Paolisso and
Giugliano 1996).
We evaluated the association between endothelial
function and obesity by angiography in patients (n = 379)
with normal or mildly diseased coronary arteries who
underwent coronary vascular activity evaluation using
intracoronary infusion of acetylcholine. Patients were
divided into three groups based on body mass index (BMI):Vascular Health and Risk Management 2005:1(3) 190
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group 1, BMI < 25 (n = 117; normal weight); group 2, BMI
25–30 (n = 149; overweight); and group 3, BMI > 30
(n = 131; obese). Although there were no significant
differences between the three groups in regard to other
cardiovascular risk factors, the percentage change of
coronary blood flow to acetylcholine was significantly lower
in the obese patients than in the normal-weight group
(85.2% ± 12% in group 1, 63.7% ± 10% in group 2, and
38.1% ± 9.6% in group 3; p = 0.009). Furthermore, by
multivariate analysis, overweight and obesity status were
independently associated with endothelial dysfunction (Al
Suwaidi et al 2001).
Weight loss may improve endothelial function indirectly
by improving blood pressure and lipid profile. In a double-
blind, placebo-controlled study using orlistat, a lipase
inhibitor that prevents fat absorption, and weight loss in
23 patients, Bergholm et al (2003) demonstrated that
lowering of LDL cholesterol rather than moderate weight
loss improved endothelial function. However, further studies
are required to confirm these observations.
There are relatively few comparable studies in the
literature. Direct measures of the effects of weight loss on
endothelial function have been reported to improve
endothelium-dependent vasodilation with the use of
 a very
low calorie diet for 2 weeks in obese hypertensive subjects
(Sasaki et al 2002). Circulating markers of endothelial
activation have been reported
 to be improved in obese
subjects after 12 weeks of caloric restriction (800 kcal/day),
achieving 9% weight loss (Ferri et al 1999), and circulating
levels of inflammatory cytokines were similarly reduced in
obese
 women after a 1-year multidisciplinary weight loss
program which achieved at least 10% reduction in weight
(Ziccardi et al 2002). In summary, the available literature
suggests beneficial effects of
 weight loss on a number of
axes related to vascular function.
 Further studies exploring
the salient features of the interventions, including the degree
of weight loss achieved and the timing of vascular measures
in relation to the restoration of a eucaloric
 diet, are needed
to better understand the interactions of
 obesity and
endothelial function.
Smoking and endothelial dysfunction
Cigarette smoking is strongly associated with atherosclerosis
and ischemic heart disease but also is a major risk factor for
acute coronary thrombosis (Chen et al 1995; Njolstad et al
1996). Indeed, 75% of sudden cardiac deaths due to acute
thrombosis are in cigarette smokers (Burke et al 1997).
Smoking causes endothelial dysfunction, and passive
smoking is associated with dose-related impairment of
endothelium-dependent dilation in healthy young adults,
suggesting early arterial damage (Hung et al 1995).
Flow-mediated dilation is significantly impaired in both
passive and active smokers when compared with non-
smokers. In passive smokers, there is an inverse relationship
between the intensity of exposure to tobacco smoke and
flow-mediated dilation.
Cigarette smoking is associated with increased platelet
thrombus formation. Small areas of denudation and
thrombus deposition are a common finding on the surface
of atheromatous plaques and are usually subclinical. In the
presence of an imbalance in the coagulation or fibrinolytic
systems, such microthrombi may propagate, ultimately
leading to arterial occlusion (Davies et al 1988; Bürrig 1991;
Celermajer et al 1996).
Endothelial dysfunction in
hyperhomocysteinemia
The nature of the link between homocysteine and
cardiovascular
 disease has not yet been clearly established.
Epidemiological studies suggested that even
 mild elevations
of plasma homocysteine are associated with an increased
risk of atherosclerosis, including coronary artery disease
(Boers et al 1985; Clarke et al 1991; Stampfer et al 1992).
Abnormal metabolism and handling of homocysteine
 have
been demonstrated after a methionine challenge in
individuals with premature atherosclerosis, most of whom
were heterozygous for cystathionine β-synthase deficiency
(Clarke et al 1991). Importantly,
 hyperhomocysteinemia may
be a modifiable risk factor for atherosclerosis,
 as plasma
homocysteine levels may be lowered by dietary
supplementation with folate and pyridoxine (Clarke et al
1991; Selhub et al 1995).
Homocysteine influences multiple vascular responses,
including coagulation, platelet function,
 vascular smooth
muscle responses, and endothelial function.
 Acute infusion
of homocysteine has been shown to induce frank endothelial
cell damage in primates (Harker et al 1983). Homocysteine
alters the production and/or bioactivity of vasoregulatory
mediators (Quere et al 1997; Zhang et al 1998), including
NO, by cultured endothelial cells. Furthermore, homo-
cysteine has been shown to impair endothelium-dependent
vasodilation and regulation of blood flow in primates and
humans (Lentz et al 1996; Woo et al 1997; Bellamy et al
1998). The exact mechanisms underlying the beneficialVascular Health and Risk Management 2005:1(3) 191
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effects of folates on the endothelium remain to be elucidated.
Thus far, most studies have focused on the homocysteine-
lowering effects of folates; however, more recently the
beneficial effects of folate treatment independent of
homocysteine lowering have been reported. Potential
mechanisms of action include antioxidant actions, effects
on cofactor availability, or direct interactions with the
enzyme endothelial NO synthase (Verhaar et al 2002).
Endothelial dysfunction as a prominent
feature of end-stage renal disease
Recently, several studies demonstrated impairment of
(coronary or peripheral, or both) endothelium-dependent
vasodilation in patients with moderate
 renal impairment, as
well as in patients with advanced renal impairment treated
by hemodialysis (Annuk et al 2001) or peritoneal dialysis
(Miyazaki et al 2000). The reasons for end-stage renal
disease patients having signs of endothelial
 dysfunction are
not fully understood but are probably multifactorial.
Increased oxidative stress, hyperhomocysteinemia,
dyslipidemia, hyperglycemia, hypertension, and retention
of L-arginine
 inhibitors may all be important contributors.
Endothelial dysfunction associated with
other diseases
A few scattered articles have described endothelial
dysfunction in other diseases, such as pulmonary hyper-
tension (Cella et al 2001), hypertrophic cardiomyopathy
(Dimitrow 2002), multiple organ dysfunction syndrome
(Aird 2003), acute renal failure (Ruschitzka et al 1999), HIV
infection (Nolan et al 2003), antiphospholipid syndrome
(Blum and Simsolo 2004), and hyperprolactinemia (Yavuz
et al 2003).
Therapy
Endothelial dysfunction is a reversible disorder, and
strategies aimed at reducing cardiovascular risk factors, such
as cholesterol
 lowering, antihypertensive therapy, smoking
cessation, ACE inhibitor therapy,
 estrogen replacement
therapy in postmenopausal women, supplementation with
folic acid, and physical exercise, also translate into an
improvement in endothelial health, further supporting the
association between risk factors and endothelial dysfunction.
Moreover, the observation that several pharmacological
interventions
 that improve endothelial function are
associated with a decrease
 in cardiovascular events
independent of risk factor modification supports the concept
that cardiovascular risk factors share
 a common pathway
that leads to endothelial dysfunction.
Various forms of therapy have been investigated in
medical studies (Table 1). The potential benefits associated
with L-arginine therapy are presumably mediated by
increased NO activity (Creager et al 1992; Boger et al 1998).
In addition to improved endothelial function, other changes
that have been described include lower plasma endothelin
concentrations, increased apoptosis of vascular cells in
intimal lesions (leading to regression of atherosclerosis and
decreased symptoms), and prevention of the progression of
atherosclerotic plaques (Rector et al 1996; Quyyumi et al
1997). The endothelium-dependent vasorelaxation with
statins results in part from endothelial NO activation. This
is independent of the cholesterol-lowering effect of these
drugs, although a reduction in oxidized LDL contributes to
this response, since oxidized LDL, but not native LDL,
down-regulates endothelial NO synthase activity; statins
increase the activity of this enzyme independently of lipid
lowering. In addition to their effect on NO, statins affect
the vasoconstrictor endothelin, further shifting the balance
toward vasodilation (O’Driscoll, Green, and Taylor 1997;
Vita et al 2000).
Fibrate therapy also improves fasting and postprandial
endothelial function in patients with type 2 diabetes. The
mechanism for this may be an increase in high-density
lipoprotein and an attenuation of postprandial lipemia and
the associated oxidative stress (Evans et al 2000).
Folate improves endothelial dysfunction by reducing the
serum levels of homocysteine. Elevated levels of
homocysteine promote endothelial dysfunction by their toxic
effects on the endothelium, probably mediated by an
increase in oxidative stress and inhibition of NO production
(Verhaar et al 1999).
More recently, the HOPE (Heart Outcome Prevention
Evaluation) trial assessed the role of an ACE inhibitor,
ramipril, in patients who were at high risk for cardiovascular
events but
 who did not have left ventricular dysfunction or
heart failure. Ramipril significantly reduced the
 rate of death,
myocardial infarction, and stroke in a broad
 range of high-
risk patients who did not have a low
 ejection fraction or
heart failure, thus suggesting that the use of ACE inhibitors
may prevent the progression of initially clinically silent
atherosclerosis (Dagenais et al 2001).
Even more recently, the insulin sensitizer thiazo-
lidinediones were found to improve endothelial function in
diabetic patients (Tack et al 1998; Pistrosch et al 2004).Vascular Health and Risk Management 2005:1(3) 192
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Table 2 Studies on the prognostic effect of coronary and peripheral endothelial dysfunction
Study type Marker of
(time of Patient Vascular endothelial End points
Reference  follow-up) population bed function examined Finding
Yataco et al 1999 Prospective 50 with PVD, Coronary  FMD Higher incidence of CAD
50 matched controls
Al Suwaidi et al Retrospective 157 with mild Coronary Acetylcholine Cardiac death, MI, 3.8% CV event rate; 
2000 (28 mo) CAD response CHF, CABG, or PCI acetylcholine response
independent predictor of
events
Schächinger et al Retrospective 147 with CAD Coronary Acetylcholine, cold MI, UA, ischemic 19% event rate; vasomotor
2000 (7.7 y) pressor test, FMD, stroke, CABG, function independent
NTG PTCA, peripheral predictor of events
bypass
Neunteufl et al Retrospective 73 with CAD Brachial FMD Death, MI, PTCA, 36% of patients with event;
2000 (5 y) or CABG FMD < 10% predictive of
events; effect lost when
controlling for extent of
CAD
Teragawa et al 2001  Prospective 30 with vasospastic Brachial FMD Impaired FMD
angina, 30 controls
Perticone et al 2001 Prospective 225 with Brachial Forearm blood CV death, MI, stroke, 12.8% CV event rate;
(32 mo) hypertension flow response to TIA, UA, CABG, acetylcholine response
acetylcholine PTCA, PVD predictor of events
Heitzer et al 2001 Prospective 281 with CAD Brachial Forearm blood CV death, MI, CABG, 32% CV event rate;
(4.5 y) flow response to PTCA, peripheral acetylcholine response
acetylcholine bypass independent predictor of
events
Gokce et al 2002 Prospective 187 undergoing Brachial FMD CV death, MI, stroke,  24% CV event rate; FMD
(30 d) vascular, surgery UA independent predictor of
events
Halcox et al 2002 Prospective 308 referred for Coronary Acetylcholine CV death, MI, 11% CV event rate;
(46 mo) cardiac response ischemic stroke, UA acetylcholine response
catheterization independent predictor of
events
Modena et al 2002 Prospective 400 hypertensive Brachial FMD Hospitalization for CV 11.7% CV event rate;
(67 mo) postmenopausal event (not otherwise failure to improve FMD
women specified) with 6 months of
antihypertensive therapy
independent predictor of
events
Gokce et al 2003 Prospective 199 undergoing Brachial FMD CV death, MI, UA, 17.5% CV event rate; FMD
(1.2 y) vascular surgery stroke independent predictor of
long-term events
Schindler et al 2003  Prospective 130 with normal Coronary Cold presser test CV death, UA, MI, 20% CV event rate; cold
(45 mo) coronary PTCA, CABG, stroke, pressor test response
angiograms peripheral bypass independent predictor of
events
Brevetti, Silvestro, Prospective 88  with PVD,  Brachial FMD in relation to  Significant correlation
Schiano, et al 2003 30 controls ankle-brachial index
Brevetti, Silvestro, Prospective Brachial Noninvasive FMD Significant correlation with
Di Giacomo, et al CV event
2003
Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; CV, cardiovascular; FMD, flow-mediated dilation;
MI, myocardial infarction; NTG, nitroglycerin; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral
vascular disease; TIA, transient ischemic attack; UA, unstable angina.Vascular Health and Risk Management 2005:1(3) 193
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Although various interventions have been shown to be
associated with
 improvement in endothelial function, little
is currently known
 about the clinical and prognostic effects
of therapeutic improvement in endothelial function.
Cholesterol lowering with statins and therapy with ACE
inhibitors are also associated with a reduction
 of myocardial
ischemia in patients with coronary artery disease. Moreover,
the improvement in coronary endothelial function by
L-arginine supplementation has been associated with a
reduction in anginal symptoms. Taken together, these
findings point out the clinical significance of therapeutic
improvement in coronary endothelial function.
Prognostic value of endothelial
dysfunction
To date, 14 published studies have examined the value of
endothelial dysfunction in prognosis. Five of these assessed
coronary endothelial dysfunction and the remainder
evaluated brachial endothelial function. Three of these
studies were retrospective analyses and the rest were
prospective studies (Table 2). We retrospectively evaluated
the long-term outcome of patients (n = 157) with normal or
mildly diseased coronary arteries who underwent coronary
vascular reactivity evaluation. Patients were divided into
three groups according to their response to intracoronary
acetylcholine: a normal endothelial function group, a mild
endothelial dysfunction group, and a moderate-to-severe
endothelial dysfunction group. We found there were no
significant differences between the various groups in regard
to traditional cardiovascular risk factors. At a mean follow-
up of 28 months, six patients in the moderate-to-severe
endothelial dysfunction group developed cardiac events,
suggesting that endothelial dysfunction is an independent
predictor for the development of cardiac events (Al Suwaidi
et al 2000).
Since the publication of our findings, several other
investigators have reported similar findings in patients with
obstructive coronary artery disease and peripheral vascular
disease. This seems to show the importance of evaluating
the function of endothelial cells as an independent predictor
in all patients with or without coronary artery disease in
either peripheral or coronary blood vessels.
Future perspectives
The future will witness increasing interest in finding
 reliable
methods of testing endothelial function; several large
noninvasive
 studies are needed to determine the predictive
value
 of brachial ultrasound testing as a potential
 predictor
of cardiovascular disease. As the measures of endothelial
dysfunction become clinically applicable,
 this may translate
into improved methods of risk assessment
 that help in
predicting, preventing, and treating cardiovascular disease.
Inflammatory markers, such as C-reactive protein, will
probably find their way into risk assessment; several
therapeutic strategies aimed at improving endothelial
function in a variety of cardiovascular disease states are
under investigation. The future holds great promise.
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